Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of gemtuzumab ozogamicin with chemotherapy and glasdegib post-transplant in favorable-intermediate risk AML
2019-003871-20Phase 3Active
- Sponsor
- GIMEMA
- Start
- May 2021
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of gemtuzumab ozogamicin and glasdegib in acute myeloid leukemia (AML) (2 arms), sponsored by GIMEMA. Started May 2021; status: active.
02
Drugs
gemtuzumab ozogamicinglasdegib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2019-003871-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003871-20.